O. Casanovas
Molecular Biology · 2005–2009
A researcher in the Science corpus: 2 papers; trusts 2 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Molecular Biology — 15 citations into it; #15,700 of 17,773 by trust here, #5,350 by citations
Whom O. Casanovas trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts O. Casanovas overall
Papers from O. Casanovas's perspective
Ordered by how strongly the researchers O. Casanovas trusts endorse each paper. Same corpus, a different order for every researcher.
- Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (Nature Cell Biology)
- Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (Nature Medicine)
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (Journal of Clinical Investigation)
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
- AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. (Cancer Cell)
- Regulation of angiogenesis by hypoxia: role of the HIF system (Nature Medicine)
- The biology of VEGF and its receptors (Nature Medicine)
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. (Cancer Cell)
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (New England Journal of Medicine)
- Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. (Cancer Cell)